Prexton Therapeutics is the first spin-off company from EPP Fund. The company is developing programs in Parkinson’s disease focused on targeting the metabotropic glutamate receptors mGluR3 and mGluR4. Prexton Therapeutics is based in Geneva, Switzerland.
Total raised: $41.07M
Investors 3
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
| - | Seroba Lif... | seroba-lif... |
| - | Forbion | forbion.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.02.2017 | Series B | $31.07M | Forbion |
| 24.02.2015 | Series A | $10M | - |
Mentions in press and media 17
| Date | Title | Description | Source |
| 01.02.2019 | Swisscom and Prexton awarded at Global Corporate Venturing S... | Over the past four years, the Global Corporate Venturing & Innovation (GCVI) Summit has grown ... | startuptic... |
| 19.03.2018 | Term Sheet — Monday, March 19 | ANTITRUST SHOWDOWN Good morning, Term Sheet readers. Paid Content How can you protect what you can... | fortune.co... |
| 16.03.2018 | Ysios realiza la 1ª desinversión de su 2º fondo tras la vent... | 16/03/2018 Nota de prensa YSIOS REALIZA LA PRIMERA DESINVERSIÓN CON SU SEGUNDO FONDO TRAS LA VENTA... | webcapital... |
| 16.03.2018 | Lundbeck to acquire Prexton for up to EUR 900 million | H. Lundbeck A/S (Lundbeck) and Prexton Therapeutics (Prexton) today announced signing of a definit... | startuptic... |
| 16.03.2018 | Lundbeck to Acquire Prexton Therapeutics, for €905M | H. Lundbeck A/S, a (OMX: LUN) Danish international pharmaceutical company, is to acquire Oss, the Ne... | finsmes.co... |
| 04.08.2017 | Prexton announces launch of phase II clinical testing in Par... | The study is double-blind, randomised, placebo-controlled parallel-arm phase II in subjects who ar... | startuptic... |
| 07.02.2017 | Term Sheet — Tuesday, February 7 | SURVEY SAYS Earlier this year I asked Term Sheet readers to take a confidence survey created by pro... | fortune.co... |
| 07.02.2017 | Prexton Therapeutics, participada por Ysios, cierra una rond... | 07/02/2017 Nota de prensa PREXTON THERAPEUTICS, PARTICIPADA POR YSIOS CAPITAL, CIERRA UNA RONDA DE... | webcapital... |
| 07.02.2017 | Prexton Therapeutics raises CHF31 million | Forbion Capital Partners (NL) and Seroba Life Sciences (IE) co-led the financing round, which incl... | startuptic... |
| 07.02.2017 | Prexton Therapeutics €29M in Series B Financing | Prexton Therapeutics, a Geneva, Switzerland and Amsterdam, The Netherlands-based biopharmaceutical c... | finsmes.co... |
Show more